Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer ’s and MS treatments
Anew study from the Office of Health Economics (OHE) confirmed that the EQ-5D, a tool commonly used in health technology assessments (HTAs) often excludes outcomes important to patients and their caregivers who rely on treatments for multiple sclerosis, Alzheimer ’s disease and sickle cell disease. (Source: The Catalyst)
Source: The Catalyst - May 19, 2022 Category: Pharmaceuticals Authors: Katie Koziara Source Type: news
Addressing social determinants of health to improve equitable access to medicines
PhRMA Awards $150,000 to Address Social Determinants of Health:Announcing the Recipients of Round 4 of the PhRMA Collaborative Actions to Reach Equity (CAREs) Grant ProgramAs part of PhRMA ’s continuing commitment to build a more just and equitable health care system, we have selected the next round of awardees in the PhRMA CAREs grant program. These recipients were selected based on their efforts to address social determinants of health to improve access to medicines in their local communities.This round of CAREs grants supports initiatives that promote access and better outcomes by removing economic, social, and other ...
Source: The Catalyst - May 19, 2022 Category: Pharmaceuticals Authors: Jackie McRae Tags: Equity Source Type: news
Gene therapies can reduce treatment burden and costs for patients with blood disorders
Anew analysis found potential gene therapies for blood disorders like hemophilia, beta thalassemia, and sickle cell disease hold promise in dramatically reducing existing treatment burdens for patients, which could result in as much as $730,000 in savings to the health care system and increase a patient ’s income by as much as $9,500 in the year following treatment. (Source: The Catalyst)
Source: The Catalyst - May 18, 2022 Category: Pharmaceuticals Authors: Katie Koziara Tags: Medicines in Development Personalized Medicine Source Type: news
Report: More than 500 medicines in development to treat disorders of the blood
Today, PhRMA released a newreport covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet medical need in the United States. To meet the demand for new treatments, companies in America ’s biopharmaceutical industry have spent years working across the biomedical ecosystem to research and develop new medicines that employ the latest in scientific and technical knowledge. (Source: The Catalyst)
Source: The Catalyst - May 18, 2022 Category: Pharmaceuticals Tags: Medicines in Development Research and Development Cancer Source Type: news
A conversation with William Pao, Chief Development Officer of Pfizer
Our industry continues working to build a more resilient, affordable and equitable health care system. I recently had the opportunity to connect with William Pao, M.D., Ph.D., Chief Development Officer and Executive Vice President for Pfizer, a PhRMA member company. (Source: The Catalyst)
Source: The Catalyst - May 17, 2022 Category: Pharmaceuticals Authors: Richard Moscicki, M.D. Source Type: news
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
This week, PhRMA sponsored The Washington Post ’s event,Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared cruciallessons learned from the pandemic on how to protect patient access to medicine and ensure the health of our robust supply chain. The event also featured PhRMA board member and Genentech CEO Alexander Hardy, who discussed Genentech ’s progress during the pandemic and how to improvehealth equity. (Source: The Catalyst)
Source: The Catalyst - May 13, 2022 Category: Pharmaceuticals Tags: Drug Cost Coronavirus Antimicrobial Resistance Source Type: news
Why drug importation is bad for Americans
Drug importation schemes are dangerous and have significant negative consequences for both individuals and our health care system. Importation refers to when governments or individuals circumvent the U.S. Food and Drug Administration ’s (FDA) regulatory review and approval process to acquire unapproved prescription drugs from other countries outside of our secure drug distribution system. Without proper FDA oversight and enforcement of laws designed to protect patient safety, which importation schemes undermine, there is incre ased potential for unsafe counterfeit, substandard or adulterated products to infiltrate the U....
Source: The Catalyst - May 12, 2022 Category: Pharmaceuticals Authors: Gabby Migliara Tags: Prescription Drug Safety Importation Drug Importation Source Type: news
Ensuring timely reauthorization of PDUFA and BsUFA
Today, the House Energy and Commerce Subcommittee on Health will be hosting a markup session on the comprehensive legislative package to reauthorize the human drug user fee programs, including the Prescription Drug User Fee Act (PDUFA VII) and the Biosimilar User Fee Act (BsUFA III). In February, PhRMA had the opportunity totestify before the subcommittee on how both programs have played, and will continue to play, a significant role in sustaining the U.S. Food and Drug Administration ’s (FDA) ability to keep pace with the number of innovative drugs, biologics and biosimilars entering the regulatory review pipeline. In M...
Source: The Catalyst - May 11, 2022 Category: Pharmaceuticals Authors: Matthew Norawong Tags: Research and Development FDA PDUFA Biologics and Biosimilars Source Type: news
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
The COVID-19 pandemic has made clear how important a stable health care system is to the American people, both during times of crisis and beyond. Patients deserve sustainable, patient-centered solutions, not temporary fixes. And while our industry has the greatest innovation ecosystem in the world, three in 10 insured Americans still face financial barriers to care. (Source: The Catalyst)
Source: The Catalyst - May 9, 2022 Category: Pharmaceuticals Authors: Emilie Signora Tags: Research and Development Health Insurance Out-of-Pocket Costs Coronavirus Source Type: news
Spotlighting a growing mental health challenge
During the pandemic, about four in 10 American adults havereported symptoms of anxiety or depressive disorder. This share is up from one in 10 adults reporting symptoms prior to the pandemic. COVID-19 has exacerbated mental health issues for many, so it ’s important that we all focus on our mental health and the mental health of those around us. (Source: The Catalyst)
Source: The Catalyst - May 9, 2022 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Research and Development Patients Mental Health Source Type: news
Annual projections from NHE compared to actual health care spending
The Centers for Medicare& Medicaid Services (CMS) recently released their National Health Expenditure (NHE) projections of health care spending in the United States through 2030. While these data are helpful when looking at the overall health care system, historically, they overestimate projected spending on retail medicines. Since 2001, CMS actuaries have overestimated the next year’s actual retail medicine spending by $1 billion or more two thirds of the time.According to the most recent data from CMS, changes in spending on retail medicines are expected to track with overall health care spending. But when we lo...
Source: The Catalyst - May 5, 2022 Category: Pharmaceuticals Authors: Katie Koziara Tags: Drug Cost Medicare Source Type: news
Study finds insurance barriers disproportionately burden patients with chronic illness
A recentPatient Experience Survey found that Americans with serious chronic conditions, including autoimmune diseases, mental health conditions and neurologic conditions were more likely than all insured Americans to report facing unaffordable out-of-pocket costs. These patients were also more likely to experience insurer-imposed barriers, like prior authorization and fail first. Accessing the medicine patients need is simply too burdensome for many Americans struggling with chronic illness.Here are three critical health insurance challenges facing patients with chronic illnesses. (Source: The Catalyst)
Source: The Catalyst - May 4, 2022 Category: Pharmaceuticals Authors: Cynthia Hicks Tags: Health Insurance Out-of-Pocket Costs Polling Source Type: news
A conversation with Barry Greene, CEO of Sage Therapeutics
Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had the opportunity to connect with PhRMA board member and Sage Therapeutics CEO Barry Greene about how we can improve mental health. (Source: The Catalyst)
Source: The Catalyst - May 4, 2022 Category: Pharmaceuticals Tags: PhRMA Member Company Mental Health Coronavirus Source Type: news
Innovative contracts continue to gain traction and improve quality of care
Innovative contracts can help bring more value to patients and the health care system. These types of payment arrangements can include: (Source: The Catalyst)
Source: The Catalyst - May 2, 2022 Category: Pharmaceuticals Authors: Katie Koziara Tags: Value-Driven Health Care Value-Based Contracting Source Type: news
Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad
More than two years into the COVID-19 pandemic, the world has witnessed the immense value of biopharmaceutical innovation. Withnumerous safe and effective vaccines and treatments developed in record time, PhRMA member companies are facilitating an unprecedented response to the pandemic. It took years of investment,collaboration across companies and borders, and the right public policies to encourage the risk-taking and research and development necessary to deliver the new treatments and vaccines. (Source: The Catalyst)
Source: The Catalyst - April 29, 2022 Category: Pharmaceuticals Authors: Ernest Kawka Tags: Intellectual Property Trade Source Type: news
